Desipramine Enrolling by Invitation Phase 4 Trials for Infantile Neuroaxonal Dystrophy Treatment

IndicationsStatusPurposePhase
Enrolling by InvitationTreatment4
clinicaltrials.gov IdentifierTitleDrugs
NCT03726996Desipramine in Infantile Neuroaxonal Dystrophy (INAD).